MISSISSAUGA, ON – GSK today announced that Health Canada has approved a new indication for Jemperli (dostarlimab for injection) in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer who are candidates for systemic therapy, based on Part 1 of the pivotal RUBY study.[1]
\n“Today’s approval supports our ambition for Jemperli to advance the standard of care for Canadian adult patients with primary advanced or recurrent dMMR/MSI-H endometrial cancer,” said Marni Freeman, Country Medical Director at GSK Canada. “This expanded approval of Jemperli offers a new care option to healthcare professionals treating this patient population with high unmet need.”
\nIn December 2021, Jemperli had previously been granted Notice of Compliance with conditions by Health Canada as a monotherapy for the treatment of adult patients with dMMR or MSI-H recurrent or advanced endometrial cancer, that has progressed on or following prior treatment with a platinum containing regimen.
\n“The Society of Gynecologic Oncology of Canada (GOC) proudly supports the inclusion of medications like dostarlimab, recognizing their potential to provide patients with valuable choices, prolong survival, and ultimately benefit women battling cancer,” expressed Dr. Alon Altman, President, The Society of Gynecologic Oncology of Canada. “We believe in the importance of a diverse and comprehensive approach to treatment, and we commend the efforts of all involved in advancing innovative solutions for women's health. Our organization remains committed to advocating for initiatives that enhance the well-being of women affected by gynecologic cancers.”
\nToday’s new indication for Jemperli was approved by Health Canada following review under Health Canada’s Priority Review policy and the Project Orbis framework of the US Food and Drug Administration (FDA) Oncology Center of Excellence, which is an international partnership designed to give cancer patients faster access to promising cancer treatments, allowing concurrent submission to and review among regulatory authorities in the US, Australia, Canada, Switzerland, Singapore and United Kingdom.
\n\"Endometrial cancer is the most common gynecologic cancer in Canada, and there have been limited new treatment options for patients over the past few decades,” said Jackie Manthorne, President, and CEO of the Canadian Cancer Survivor Network (CCSN). “The CCSN is pleased to see a newly approved innovative treatment option for patients in Canada. We hope that new treatments like dostarlimab will not be delayed by our Canadian reimbursement and funding systems. Patients shouldn’t have to wait, because cancer certainly can't wait!\"
\nThe new expanded approval in Canada is supported by interim analysis results from Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial. The RUBY trial data were presented at the European Society for Medical Oncology (ESMO) Virtual Plenary and Society of Gynecologic Oncology (SGO) Annual Meeting on March 27, 2023, and were simultaneously published in The New England Journal of Medicine.[2]
\nAbout endometrial cancer
\nEndometrial cancer is one of the most common gynaecologic cancers in developed countries,[3] and there are about 8,100 new cases of endometrial cancer diagnosed every year in Canada [4]. Approximately 15-20% of patients with endometrial cancer will be diagnosed with advanced disease at the time of diagnosis. [5] [6] An estimated 20-29% of all endometrial cancers are dMMR/MSI-H. [7] Chemotherapy has been the current standard of care for the majority of patients with primary advanced or recurrent endometrial cancer, and many patients eventually experience disease progression. [8]
\nAbout RUBY
RUBY is a two-part global, randomized, double-blind, multicentre phase III trial of patients with primary advanced or recurrent endometrial cancer. Part 1 is evaluating dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus carboplatin-paclitaxel plus placebo followed by placebo.
\nThe dual-primary endpoints in Part 1 are investigator-assessed progression-free survival (PFS) based on the Response Evaluation Criteria in Solid Tumours v1.1 and overall survival (OS). The statistical analysis plan included pre-specified analyses of PFS in the dMMR/MSI-H and ITT populations and OS in the overall population. Pre-specified exploratory analyses of PFS in the mismatch repair proficient (MMRp)/microsatellite stable (MSS) population and OS in the dMMR/MSI-H populations were also performed. RUBY Part 1 included a broad population, including histologies often excluded from clinical trials such as carcinosarcoma and serous carcinoma.
\n
About Jemperli (dostarlimab for injection)
Jemperli is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2. [9]
\nIn Canada, Jemperli (dostarlimab for injection) is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer who are candidates for systemic therapy, and as monotherapy for the treatment of adult patients with dMMR or MSI-H recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen.
\nPlease consult the Product Monograph at www.gsk.ca for complete safety information. The Product Monograph is also available by calling 1-800-387-7374.
\nGSK in oncology
\nGSK is committed to maximizing patient survival through transformational medicines, with a current focus on breakthroughs in immuno-oncology and tumor-cell targeting therapies, and development in haematologic malignancies, gynaecologic cancers and other solid tumours.
\nAbout GSK
\nGSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.ca.
\nReferences
\n1 Jemperli Product Monograph (2023), GSK. Available at: www.gsk.ca
\n2 Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023;388(23):2145-2158.
\n3 Faizan U, Muppidi V. Uterine Cancer. [Updated 2022 Sep 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available at: https://www.ncbi.nlm.nih.gov/books/NBK562313/.
\n4 Lee, S. (n.d.). Canadian cancer statistics. Canadian Cancer Society. https://cancer.ca/en/research/cancer-statistics/canadian-cancer-statistics.
\n5 Cerner Enviza CancerMPact® Patient Metrics 2022. CMP:CancerMPact® [Patient Metrics], Cerner Enviza. Available from www.cancermpact.com. Accessed 11 May 2023.
\n6 CancerMPact® [Treatment Architecture], Cerner Enviza. Available from www.cancermpact.com. Accessed 11 May 2023.
\n7 Cerner Enviza CancerMPact® [Treatment Architecture]. Available from www.cancermpact.com. Accessed 14 Apr 2023.
\n8 Halla K. Emerging Treatment Options for Advanced or Recurrent Endometrial Cancer. J Adv Pract Oncol. 2022 Jan;13(1):45-59. doi: 10.6004/jadpro.2022.13.1.4. Epub 2022 Feb 1. PMID: 35173988; PMCID: PMC8805805.
\n9 Laken H, Kehry M, Mcneeley P, et al. Identification and characterization of TSR-042, a novel anti-human PD-1 therapeutic antibody. European Journal of Cancer. 2016;69,S102. doi:10.1016/s0959-8049(16)32902-1.
\n","useGreyBackground":false,"fullWidth":false},{"type":"varied-signpost-grid","title":"Find more about us","layoutPattern":1,"pages":[{"title":"Company","content":"We unite science, technology and talent to get ahead of disease together","image":{"src":"/media/ksueo3le/immuno-oncology-science-image.jpg?width=480&height=270&format=webp&quality=100&v=1dbf19a8b311970","alt":"3D rendering of immuno-oncology cells","darkModeSrc":"/media/ksueo3le/immuno-oncology-science-image.jpg?width=480&height=270&format=webp&quality=90&v=1dbf19a8b311970"},"link":{"text":"Company","href":"/en-ca/company/","openInNewWindowText":null}},{"title":"Press releases","content":"Keep up to date with our news and recent announcements","image":{"src":"/media/m0ffxymm/gskh_3_2022_comspc_19_hess.jpg?rxy=0.41046277665995978,0.35347432024169184&width=480&height=270&format=webp&quality=100&v=1dbf19a8f3897f0","alt":"Two blurred figure in a large room.","darkModeSrc":"/media/m0ffxymm/gskh_3_2022_comspc_19_hess.jpg?rxy=0.41046277665995978,0.35347432024169184&width=480&height=270&format=webp&quality=90&v=1dbf19a8f3897f0"},"link":{"text":"Press releases","href":"/en-ca/media/press-releases/","openInNewWindowText":null}}],"hidePageDescription":false,"useGreyBackground":false}]},"id":6399,"docCheckLogout":null,"pageType":"pressReleasePage","languageCode":"en-CA","theme":"light","breadcrumb":{"ariaLabel":"Breadcrumb","links":[{"text":"Home","href":"/en-ca/","openInNewWindowText":null},{"text":"Media","href":"/en-ca/media/","openInNewWindowText":null},{"text":"Press releases","href":"/en-ca/media/press-releases/","openInNewWindowText":null},{"text":"Jemperli (dostarlimab for injection) plus carboplatin and paclitaxel approved in Canada as a treatment option for primary advanced or recurrent dMMR/MSI-H endometrial cancer","href":"/en-ca/media/press-releases/jemperli-dostarlimab-for-injection-plus-carboplatin-and-paclitaxel-approved-in-canada-as-a-treatment-option-for-primary-advanced-or-recurrent-dmmrmsi-h-endometrial-cancer/","openInNewWindowText":null}]},"pageName":"Jemperli (dostarlimab for injection) plus carboplatin and paclitaxel approved in Canada as a treatment option for primary advanced or recurrent dMMR/MSI-H endometrial cancer","topNav":{"homeLink":{"text":"GSK Homepage","href":"/en-ca/","openInNewWindowText":null},"topBar":{"currentLocation":{"isGlobal":false,"text":"Canada (EN/FR)"},"languageSelector":{"currentLanguage":"English","currentLanguageMobile":"EN","selectableLanguages":[{"opensInNewWindow":"Opens in a new window","desktopName":"English","mobileName":"EN","code":"/en-ca/","target":null},{"opensInNewWindow":"Opens in a new window","desktopName":"Français","mobileName":"FR","code":"/fr-ca/","target":null}]},"darkModeSwitch":{"text":"Dark Mode","tooltipText":"
Switch to dark mode to head towards a more sustainable world together. More info.
"},"globalSiteLink":{"text":"Global","href":"https://www.gsk.com","target":"_blank","openInNewWindowText":"Opens in a new window"},"locationSelector":{"text":"Location selector","href":"/en-ca/locations/","openInNewWindowText":null},"healthCareLink":{"text":"Healthcare professionals","href":"https://gskpro.com","target":"_blank","openInNewWindowText":"Opens in a new window"},"contactUs":{"text":"Contact us","href":"/en-ca/contact-us/","openInNewWindowText":null},"search":"Search","backToMain":"Back to main","menu":"Menu","closeMenu":"Close menu","animationsToggleModel":{"enable":true,"activeText":"Pause video","inactiveText":"Play video"}},"nodes":[{"tooltip":null,"hasBorderRight":false,"title":"Company","url":"/en-ca/company/","nodes":[{"title":"Purpose, strategy and culture","url":"/en-ca/company/purpose-strategy-and-culture/","nodes":[],"isActive":false},{"title":"At a glance","url":"/en-ca/company/at-a-glance/","nodes":[],"isActive":false},{"title":"Canada leadership team","url":"/en-ca/company/canada-leadership-team/","nodes":[],"isActive":false},{"title":"Policies","url":"/en-ca/company/policies/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Global Outstanding people","image":{"src":"/media/l20f4brn/navthumb-web09-header-gskh_2_2022_smtspc_37_hess.jpg?rxy=0.355,0.36888888888888888&width=329&height=185&format=webp&quality=100&v=1dbf19a8f7504b0","alt":"Man smiling during a meeting","darkModeSrc":"/media/l20f4brn/navthumb-web09-header-gskh_2_2022_smtspc_37_hess.jpg?rxy=0.355,0.36888888888888888&width=329&height=185&format=webp&quality=90&v=1dbf19a8f7504b0"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/company/outstanding-people/","target":"_blank","openInNewWindowText":"Opens in a new window"}},{"text":"Global policy positions","image":{"src":"/media/zx5kpb4m/gsk_texture_fluid_03_a_cmyk_web-size.jpg?width=329&height=185&format=webp&quality=100&v=1dbf19a9142e6e0","alt":"Orange texture","darkModeSrc":"/media/zx5kpb4m/gsk_texture_fluid_03_a_cmyk_web-size.jpg?width=329&height=185&format=webp&quality=90&v=1dbf19a9142e6e0"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/company/policy-positions","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":false,"title":"Innovation","url":"/en-ca/innovation/","nodes":[{"title":"Therapeutic areas","url":"/en-ca/innovation/therapeutic-areas/","nodes":[],"isActive":false},{"title":"Trials","url":"/en-ca/innovation/trials/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Global pipeline","image":{"src":"/media/xskjorin/ware_3_2022_prodqc_14_hess.jpg?width=329&height=185&format=webp&quality=100&v=1dbf19a91879100","alt":"Science experiment","darkModeSrc":"/media/xskjorin/ware_3_2022_prodqc_14_hess.jpg?width=329&height=185&format=webp&quality=90&v=1dbf19a91879100"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/innovation/pipeline/","target":"_blank","openInNewWindowText":"Opens in a new window"}},{"text":"Global Behind the science magazine","image":{"src":"/media/ksueo3le/immuno-oncology-science-image.jpg?width=329&height=185&format=webp&quality=100&v=1dbf19a8b311970","alt":"3D rendering of immuno-oncology cells","darkModeSrc":"/media/ksueo3le/immuno-oncology-science-image.jpg?width=329&height=185&format=webp&quality=90&v=1dbf19a8b311970"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/behind-the-science-magazine/","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":false,"title":"Products","url":"/en-ca/products/","nodes":[{"title":"Products A-Z","url":"/en-ca/products/products-a-z/","nodes":[],"isActive":false},{"title":"Stiefel - Dermatology","url":"/en-ca/products/stiefel-dermatology/","nodes":[],"isActive":false},{"title":"Report a possible side effect","url":"/en-ca/products/report-a-possible-side-effect/","nodes":[],"isActive":false},{"title":"Patient Support and Healthcare Support Services","url":"/en-ca/products/patient-support-and-healthcare-support-services/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Report a possible side effect","image":{"src":"/media/0otczyps/web03-header-stvg_2_2022_port_5_hess_nav.jpg?rxy=0.53,0.48444444444444446&width=329&height=185&format=webp&quality=100&v=1dbf19a8dba8370","alt":"Woman in a labcoat smiling at the camera","darkModeSrc":"/media/0otczyps/web03-header-stvg_2_2022_port_5_hess_nav.jpg?rxy=0.53,0.48444444444444446&width=329&height=185&format=webp&quality=90&v=1dbf19a8dba8370"},"link":{"text":"Featured section","href":"/en-ca/products/report-a-possible-side-effect/","openInNewWindowText":null}},{"text":"GSKPro","image":{"src":"/media/i5mft2xn/navthumb_stvg_03_2022_port_32_eagle_orange-1.jpg?rxy=0.48,0.23555555555555555&width=329&height=185&format=webp&quality=100&v=1dbf19a8e994ab0","alt":"Two people hanging out together in front of an orange background","darkModeSrc":"/media/i5mft2xn/navthumb_stvg_03_2022_port_32_eagle_orange-1.jpg?rxy=0.48,0.23555555555555555&width=329&height=185&format=webp&quality=90&v=1dbf19a8e994ab0"},"link":{"text":"Featured website","href":"https://gskpro.com/en-ca/","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":true,"title":"Responsibility","url":"/en-ca/responsibility/","nodes":[{"title":"Inclusion","url":"/en-ca/responsibility/inclusion/","nodes":[],"isActive":false},{"title":"Ethical standards","url":"/en-ca/responsibility/ethical-standards/","nodes":[{"title":"Engaging with healthcare professionals","url":"/en-ca/responsibility/ethical-standards/engaging-with-healthcare-professionals/","nodes":[],"isActive":false},{"title":"Transparency reporting","url":"/en-ca/responsibility/ethical-standards/transparency-reporting/","nodes":[],"isActive":false},{"title":"Grants and donations","url":"/en-ca/responsibility/ethical-standards/grants-and-donations/","nodes":[],"isActive":false}],"isActive":false},{"title":"Charitable investments in Canada","url":"/en-ca/responsibility/charitable-investments-in-canada/","nodes":[],"isActive":false},{"title":"Accessibility","url":"/en-ca/responsibility/accessibility/","nodes":[{"title":"GSK’s Multi-Year Accessibility Plan","url":"/en-ca/responsibility/accessibility/gsk-s-multi-year-accessibility-plan/","nodes":[],"isActive":false}],"isActive":false},{"title":"Patient group funding","url":"/en-ca/responsibility/patient-group-funding/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Ethical standards","image":{"src":"/media/uxlkxzrj/ware_3_2022_prodqc_38_hess-1.jpg?width=329&height=185&format=webp&quality=100&v=1dbf19a8db07150","alt":"Group working together in a lab","darkModeSrc":"/media/uxlkxzrj/ware_3_2022_prodqc_38_hess-1.jpg?width=329&height=185&format=webp&quality=90&v=1dbf19a8db07150"},"link":{"text":"Featured section","href":"/en-ca/responsibility/ethical-standards/","openInNewWindowText":null}},{"text":"Global responsibility","image":{"src":"/media/olhgq5am/stvg_2_2022_smtlab_2_hess-1920x1080px.jpeg?rxy=0.41851106639839036,0.37764350453172207&width=329&height=185&format=webp&quality=100&v=1dbf19a8dc8db50","alt":"Man adjusting glasses working on a computer","darkModeSrc":"/media/olhgq5am/stvg_2_2022_smtlab_2_hess-1920x1080px.jpeg?rxy=0.41851106639839036,0.37764350453172207&width=329&height=185&format=webp&quality=90&v=1dbf19a8dc8db50"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/responsibility/","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":false,"title":"Media","url":"/en-ca/media/","nodes":[{"title":"Press releases","url":"/en-ca/media/press-releases/","nodes":[],"isActive":true},{"title":"Media contacts","url":"/en-ca/media/media-contacts/","nodes":[],"isActive":false},{"title":"Resource library","url":"/en-ca/media/resource-library/","nodes":[],"isActive":false}],"isActive":true,"promos":[{"text":"Global press releases","image":{"src":"/media/zyvhqfdo/gsk-house-view.jpg?width=329&height=185&format=webp&quality=100&v=1dbf19a9120dff0","alt":"Artwork in GSK Building","darkModeSrc":"/media/zyvhqfdo/gsk-house-view.jpg?width=329&height=185&format=webp&quality=90&v=1dbf19a9120dff0"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/media/press-releases/","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":false,"title":"Careers","url":"/en-ca/careers/","nodes":[{"title":"Life at GSK","url":"/en-ca/careers/life-at-gsk/","nodes":[],"isActive":false},{"title":"Experienced professionals","url":"/en-ca/careers/experienced-professionals/","nodes":[],"isActive":false},{"title":"Early careers","url":"/en-ca/careers/early-careers/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Global how we hire","image":{"src":"/media/sbrno3h2/gsk_rix_24_10_18_p_d2_s4_064-how-we-hire-1920x960px.jpg?rxy=0.579476861167002,0.32661290322580644&width=329&height=185&format=webp&quality=100&v=1dbf19a8f7fb310","alt":"People talking together in a meeting","darkModeSrc":"/media/sbrno3h2/gsk_rix_24_10_18_p_d2_s4_064-how-we-hire-1920x960px.jpg?rxy=0.579476861167002,0.32661290322580644&width=329&height=185&format=webp&quality=90&v=1dbf19a8f7fb310"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/careers/how-we-hire/","target":"_blank","openInNewWindowText":"Opens in a new window"}},{"text":"Global future leaders program","image":{"src":"/media/vgal0nno/gskh-2-2022-smtspc-11-hess-future-leaders-graduate-programme-1920x960px.jpg?rxy=0.42655935613682094,0.3911290322580645&width=329&height=185&format=webp&quality=100&v=1dbf19a8f2d4d50","alt":"Two people conversing together in an office","darkModeSrc":"/media/vgal0nno/gskh-2-2022-smtspc-11-hess-future-leaders-graduate-programme-1920x960px.jpg?rxy=0.42655935613682094,0.3911290322580645&width=329&height=185&format=webp&quality=90&v=1dbf19a8f2d4d50"},"link":{"text":"Spotlight on","href":"https://www.gsk.com/en-gb/careers/early-talent/future-leaders-graduate-programme","target":"_blank","openInNewWindowText":"Opens in a new window"}}]}],"skipToContent":null,"skipToSearch":null,"typeaheadSearch":{"apiEndpoint":"api/search/typeahead?siteContainerId=5769","searchFieldPlaceholderText":"Enter a search term...","searchPage":"/en-ca/search/","ariaLabel":"Submit form"},"ariaLabel":"Global navigation"},"footer":{"logo":null,"copyrightText":"This website is intended for visitors looking for information on GSK Canada. Other market sites can be reached by visiting our location selector.
\n© 2001-2026 GSK plc. All rights reserved. Trademarks are owned by or licensed to the GSK group of companies.
\nGSK plc. Registered in England and Wales No. 3888792.
\nGlaxoSmithKline Inc. 100 Milverton Drive, Suite 800, Mississauga, ON L5R 4H1
","modernSlaveryStatement":{"name":"GSK Modern Slavery Act Statement 2023","url":"/media/iwinetmy/modern-slavery-act-statement-2023.pdf","fileExtension":"PDF","fileSize":"154.2KB","type":"file","target":"_blank","openInNewWindowText":"Opens in a new window"},"sections":{"socialMedia":{"columnTitle":"Follow us on:","socialMediaItems":[{"globalLink":{"text":null,"href":"https://twitter.com/gskca","openInNewWindowText":null},"localLink":null,"ariaLabel":"Follow us on X","customIcon":null,"showPopupMenu":false,"type":"X"},{"globalLink":{"text":null,"href":"https://www.facebook.com/GSK","openInNewWindowText":null},"localLink":null,"ariaLabel":"Follow us on Facebook","customIcon":null,"showPopupMenu":false,"type":"Facebook"},{"globalLink":{"text":null,"href":"http://www.youtube.com/GSK","openInNewWindowText":null},"localLink":null,"ariaLabel":"Follow us on Youtube","customIcon":null,"showPopupMenu":false,"type":"Youtube"},{"globalLink":{"text":null,"href":"http://www.linkedin.com/company/glaxosmithkline","openInNewWindowText":null},"localLink":null,"ariaLabel":"Follow us on LinkedIn","customIcon":null,"showPopupMenu":false,"type":"LinkedIn"},{"globalLink":{"text":null,"href":"https://www.instagram.com/gsk/","openInNewWindowText":null},"localLink":null,"ariaLabel":"Follow us on Instagram","customIcon":null,"showPopupMenu":false,"type":"Instagram"}]},"columns":[{"columnTitle":"GSK websites","links":[{"text":"GSK Global website","href":"https://www.gsk.com","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Market website selector","href":"/en-ca/locations/","openInNewWindowText":null},{"text":"Global Behind the science magazine","href":"https://www.gsk.com/en-gb/behind-the-science/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"GSKPro for healthcare professionals","href":"https://gskpro.com","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"GSK Medical for healthcare professionals","href":"https://medical.gsk.com/en-ca/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"ViiV Healthcare","href":"https://viivhealthcare.com/en-ca/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Supplier website","href":"https://supplier.gsk.com/","target":"_blank","openInNewWindowText":"Opens in a new window"}]},{"columnTitle":"Quick links","links":[{"text":"Company","href":"/en-ca/company/","openInNewWindowText":null},{"text":"Innovation","href":"/en-ca/innovation/","openInNewWindowText":null},{"text":"Products","href":"/en-ca/products/","openInNewWindowText":null},{"text":"Responsibility","href":"/en-ca/responsibility/","openInNewWindowText":null},{"text":"Media","href":"/en-ca/media/","openInNewWindowText":null},{"text":"Careers","href":"/en-ca/careers/","openInNewWindowText":null}]},{"columnTitle":"Get in touch","links":[{"text":"Contact us","href":"/en-ca/contact-us/","openInNewWindowText":null},{"text":"Report a possible side effect","href":"/en-ca/products/report-a-possible-side-effect/","openInNewWindowText":null},{"text":"GSK Speak up","href":"https://www.gsk.com/speakup","target":"_blank","openInNewWindowText":"Opens in a new window"}]}]},"bottomLinks":[{"text":"Accessibility","href":"/en-ca/responsibility/accessibility/","target":"_parent","openInNewWindowText":"Opens in a new window"},{"text":"Terms of use","href":"/en-ca/terms-of-use/","target":"_parent","openInNewWindowText":"Opens in a new window"},{"text":"Cookie policy","href":"/en-ca/cookie-policy/","target":"_parent","openInNewWindowText":"Opens in a new window"},{"text":"Privacy notice","href":"https://privacy.gsk.com/en-ca/privacy-notice/general/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Sitemap","href":"/en-ca/sitemap/","openInNewWindowText":null}],"continueToLink":null,"legalApprovalText":""},"sharing":{"description":"GSK today announced that Health Canada has approved a new indication for Jemperli (dostarlimab)","og":[{"property":"og:title","content":"Jemperli (dostarlimab for injection) plus carboplatin and paclitaxel approved in Canada as a treatment option for primary advanced or recurrent dMMR/MSI-H endometrial cancer"},{"property":"og:description","content":"GSK today announced that Health Canada has approved a new indication for Jemperli (dostarlimab)"},{"property":"og:image","content":"https://ca.gsk.com/media/rsznn1hu/packing2.jpg?width=600&format=webp&quality=100&v=1dbf19a78b5ce80"},{"property":"og:url","content":"https://ca.gsk.com/en-ca/media/press-releases/jemperli-dostarlimab-for-injection-plus-carboplatin-and-paclitaxel-approved-in-canada-as-a-treatment-option-for-primary-advanced-or-recurrent-dmmrmsi-h-endometrial-cancer/"}],"twitter":[{"name":"twitter:card","content":"summary_large_image"},{"name":"twitter:site","content":"@gsk"},{"name":"twitter:title","content":"Jemperli (dostarlimab for injection) plus carboplatin and paclitaxel approved in Canada as a treatment option for primary advanced or recurrent dMMR/MSI-H endometrial cancer"},{"name":"twitter:description","content":"GSK today announced that Health Canada has approved a new indication for Jemperli (dostarlimab)"},{"name":"twitter:image","content":"https://ca.gsk.com/media/rsznn1hu/packing2.jpg?width=600&format=webp&quality=100&v=1dbf19a78b5ce80"},{"name":"twitter:url","content":"https://ca.gsk.com/en-ca/media/press-releases/jemperli-dostarlimab-for-injection-plus-carboplatin-and-paclitaxel-approved-in-canada-as-a-treatment-option-for-primary-advanced-or-recurrent-dmmrmsi-h-endometrial-cancer"}]},"stickyShare":null,"exitSitePreferences":{"popupEnabled":true,"title":"You are leaving our website","texts":"The information you are about to be referred to may not comply with the local regulatory requirements. Further information relevant to the local environment is available from the company or via the Product Information.
","continueText":"Continue","cancelText":"Cancel","exclusionUrls":["http://gsk.com/","https://www.gsk.com","https://innovation.gsk.com/","https://www.gskgrants.com","https://www.gskforyou.com/","https://www.gsk-clinicalstudyregister.com/","https://www.gsk.com/en-gb/about-us/policies-codes-and-standards/","http://www.gsk.com/en-gb/about-us/policies-codes-and-standards/","https://www.gsk.com/en-gb/products/stiefel-dermatology/","https://www.gsk.com/en-gb/products/viiv-healthcare/","https://www.contactus.gsk.com/callback/index.html","https://www.gsksource.com/gskprm/en/US/adirect/gskprm?cmd=Home&entryPoint=adirect&messageType=Home","https://www.gsksource.com/pharma/content/gsk/source/us/en.html","http://www.msds-gsk.com/","https://www.gsk.com/en-gb/investors/shareholder-information/","http://www.gsk.com/en-gb/investors/","https://www.gsk.com/en-gb/investors/corporate-reporting/","https://www.gsk.com/en-gb/investors/product-pipeline/","http://www.gskgrants.com/","https://www.gsksource.com/gskprm/en/US/adirect/gskprm?cmd=Home&entryPoint=adirect&messageType=Home","https://www.gsk.com/media/2941/human-rights-statement-policy.pdf","http://www.gsk.com/media/280848/human-rights-statement-policy.pdf","https://www.gsk.com/en-gb/business-to-business/","https://supplier.gsk.com/irj/portal/public?guest_user=SUP_GUEST_EN","https://www.gsk.com/en-gb/business-to-business/","https://supplier.gsk.com/irj/portal/public?guest_user=SUP_GUEST_EN","http://twitter.com/GSK","http://www.gsk-clinicalstudyregister.com/","https://www.gsk.com/en-gb/media/press-releases/new-multi-country-survey-reveals-need-for-improved-awareness-around-long-term-impact-and-appropriate-use-of-corticosteroids-in-sle-management/","http://www.gskforyou.com/","https://www.gskforyou.com/prescription-resource-assistance/immunology-respiratory/","https://www.contactus.gsk.com/callback.html","https://www.gsk.com/en-gb/about-us/governance/global-compliance/","https://www.gsk.com/en-gb/careers/physicians/","https://www.gsk.com/en-gb/contact-us/worldwide/","https://access.gsk.com/password/","https://access.gsk.com/selfservice/static/login.jsp?TYPE=33554433&REALMOID=06-c7edf5ec-5585-100d-83b1-84797f88fc89&GUID=&SMAUTHREASON=0&METHOD=GET&SMAGENTNAME=-SM-90R5K5a0NsTyKRhPyTIn3A3B5ovKkqcehflGRUrUNusjZdRaPY%2bWUozEFizs1bMg&TARGET=-SM-https%3a%2f%2fuksah%2egsk%2ecom%2fswh_uk_win_ns%2fcommunications%2femployee%2femployees%2ehtm","https://supplier.gsk.com/irj/portal/public?guest_user=SUP_GUEST_EN","https://ascend.cvmsolutions.com/Account/Login?client=gsk","https://www.gsk.com/media/5097/our-approach-to-responsible-business_sept-18.pdf","https://www.gsk.com/en-gb/responsibility/responsibility-reports-data/","https://www.gsk.com/media/2538/gsk-materiality-process.pdf","https://www.gsk.com/en-gb/responsibility/access-to-healthcare/","https://www.gsk.com/en-gb/responsibility/our-people/","https://www.gsk.com/en-gb/responsibility/environment/","https://www.gsk.com/en-gb/responsibility/operating-responsibly/","https://www.gsk.com/media/4552/our-code-of-practice.pdf","https://www.gsk.com/media/4552/our-code-of-practice.pdf#page=10","https://www.gsk.com/media/4552/our-code-of-practice.pdf#page=35","https://www.gsk.com/media/4552/our-code-of-practice.pdf#page=35","https://www.gsk.com/en-gb/media/resource-centre/","https://www.gsk.com/en-gb/media/image-and-video-library/","https://www.gsk.com/en-gb/media/rss-feeds/","https://www.gsk.com/en-gb/investors/corporate-reporting/annual-report-2017/","https://www.gsk.com/en-gb/careers/experienced-professionals/business-operations/","https://www.gsk.com/en-gb/careers/experienced-professionals/engineering/","https://www.gsk.com/en-gb/careers/experienced-professionals/manufacturing-and-supply/","https://www.gsk.com/en-gb/careers/experienced-professionals/marketing-and-communications/","https://www.gsk.com/en-gb/careers/experienced-professionals/research-and-development/","https://www.gsk.com/en-gb/careers/experienced-professionals/sales/","https://www.gsk.com/media/5041/rd-update-slides-hal-barron.pdf","https://www.gsk.com/en-gb/careers/meet-our-people/","https://www.gsk.com/en-gb/responsibility/our-people/employee-volunteering/","https://gskearlytalent.avature.net/landingpage","https://www.gsk.com/en-gb/careers/apprentices-students-and-graduates/future-leaders-graduate-programme/","https://www.gsk.com/en-gb/responsibility/our-people/volunteer-stories/","https://www.gsk.com/en-gb/partnerships/bioelectronics-research-network/","https://www.gsk.com/en-gb/research/our-approach/open-innovation/","https://www.youtube.com/channel/UChWuz9ZDceHYHXmJVJ4hF8Q","https://www.youtube.com/channel/UCN1XeWQWLVhFLHQwZl93jFQ","https://www.youtube.com/channel/UCwQyIfV4pLlsZGuN7fiZm2w","https://www.gsk.com/en-gb/media/press-releases/karenann-terrell-appointed-chief-digital-technology-officer-gsk/","https://www.gsk.com/en-gb/careers/meet-our-people/lindsay-rd-uk/","http://uk.gsk.com/en-gb/careers/apprenticeships/","https://www.gsk.com/media/4931/gsk-quick-facts.pdf","https://ie.gsk.com/ie/careers/apprenticeships/","http://au.gsk.com/en-au/careers/apprenticeships/","http://sg.gsk.com/en-sg/careers/","https://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect/","https://gsk.i-sight.com/landing-page/","https://www.gskforyou.com/","https://privacy.gsk.com/en-ca/privacy-notice/general","http://annualreport.gsk.com/","https://privacy.gsk.com","https://www.gsk.com/en-gb/company/outstanding-people/","https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-fy-2021-reported-sales-of-34-billion-stable-at-aer-plus5-cer/","https://www.gsk.com/media/7473/esg-performance-report-2021.pdf","https://www.gsk.com/en-gb/behind-the-science/","https://gskpro.com/","https://viivhealthcare.com/","https://gsk.supplierone.co/","https://www.gsk.com/speakup","https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/","https://www.gsk.com/en-gb/research-and-development/our-approach-to-rd/","https://www.gsk.com/en-gb/innovation/partnerships/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/infectious-diseases/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/hiv/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/oncology/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/immunology/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/opportunity-driven/","https://www.gsk.com/media/8519/the-code-printable-version.pdf","https://www.gsk.com/en-gb/company/policy-positions","https://www.gsk.com/en-gb/company/codes-standards-and-reports","https://www.gsk.com/en-gb/innovation/pipeline/","https://www.gsk.com/en-gb/innovation/rd-locations/","https://www.gsk.com/en-gb/innovation/research-and-development-approach/","https://www.gsk-studyregister.com","https://gskpro.com/en-ca/","https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/","https://www.gsk.com/en-gb/responsibility/pricing-and-access/","https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/","https://www.gsk.com/en-gb/responsibility/diversity-equity-and-inclusion/","https://www.gsk.com/en-gb/responsibility/environmental-sustainability/","https://www.gsk.com/en-gb/responsibility/product-governance/","https://www.gsk.com/en-gb/responsibility/ethical-standards/","https://annualreport.gsk.com/","https://www.gsk.com/en-gb/media/media-contacts/","https://www.gsk.com/en-gb/media/media-library/","https://www.gsk.com/en-gb/media/social-media/","https://www.gsk.com/en-gb/media/our-response-to-the-situation-in-ukraine/","https://www.gsk.com/en-gb/careers/featured-careers/","https://www.gsk.com/en-gb/careers/how-we-hire/","https://www.gsk.com/en-gb/careers/our-global-and-regional-hubs/","https://www.gsk.com/en-gb/careers/how-we-hire/frequently-asked-questions/","https://www.gsk.com/en-gb/careers/","https://www.gsk.com/en-gb/careers/early-talent/kickstart-your-career/","https://www.gsk.com/en-gb/careers/early-talent/apprentice-programmes/","https://www.gsk.com/en-gb/careers/early-talent/work-experience-placements-and-internships/","https://www.gsk.com/en-gb/company/governance/compliance/","https://gskpro.com","https://www.gsk-studyregister.com/","https://www.gsk.com/en-gb/company/gsk-at-a-glance/","https://www.gsk.com/en-gb/innovation/technologies/","https://www.gsk.com/en-gb/innovation/trials/diversity-in-clinical-trials/","https://www.gsk.com/en-gb/responsibility/","https://www.gsk.com/en-gb/careers/early-talent/future-leaders-graduate-programme","https://privacy.gsk.com/en-ca/privacy-notice/","https://us.gsk.com/en-us/about-us/us-community-partnerships/stem-education/philadelphia-stem-equity-collective/","https://www.gsk.com/en-gb/responsibility/charitable-partnerships/","https://supplier.gsk.com/irj/portal/public","https://privacy.gsk.com/en-ca/privacy-notice/general/","https://twitter.com/gskca","https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2022-performance-with-full-year-sales-of-293-billion/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/respiratoryimmunology/","https://www.gsk.com/en-gb/investors/financial-reports/annual-report-2023/","https://www.gsk.com/en-gb/responsibility/environment/climate/","https://supplier.gsk.com/"]},"settings":{"optionalStylesheetLink":"/media/bbcob5qx/optional_style_ca.css","themeColorHexCode":null,"headerLogoLightTheme":null,"headerLogoDarkTheme":null,"footerLogo":{"src":"https://ca.gsk.com/media/s3hkylbc/gsk-logo_png.png?width=104&format=webp&quality=100&v=1dbf19a937d1f70","alt":"Gsk Logo Png","darkModeSrc":"https://ca.gsk.com/media/s3hkylbc/gsk-logo_png.png?width=104&format=webp&quality=90&v=1dbf19a937d1f70"},"scripts":[{"pageLocation":"Top","text":" \n"}],"globalWebsiteLink":{"text":"Global","href":"https://www.gsk.com","target":"_blank","openInNewWindowText":"Opens in a new window"},"googleMapsApiKey":"AIzaSyA2QMg4Ww6djPKb7b9BraQn4kgJmDaLblg","textToSpeechApiKey":"","bingVerificationCode":"","googleAnalytics":"","siteTitle":" | GSK Canada"},"pageSettings":{"disableBackToTopButton":false,"backToTopButtonText":"Back to top","robotsNoFollow":false,"robotsNoIndex":false,"canonicalUrl":"https://ca.gsk.com/en-ca/media/press-releases/jemperli-dostarlimab-for-injection-plus-carboplatin-and-paclitaxel-approved-in-canada-as-a-treatment-option-for-primary-advanced-or-recurrent-dmmrmsi-h-endometrial-cancer/"},"tealiumSettings":{"enabled":false,"data":""},"entryPopup":null,"protectedPage":false,"schema":null}